Treace Medical Concepts Logo
US89455T1097
A3CM04
TMCI

Treace Medical Concepts

Kurser indlæses...

Prognose

Analytikernes gennemsnitlige kursmål er 5,92 € (-74,13 %). Medianen er 5,92 € (-74,13 %).

Køb
  3
Behold
  5
Sælg
  1

Diskussioner i communityet

Der er endnu ingen diskussion om dette aktiv.

Start diskussion

  • Treace Medical beats Q2 forecasts; shares jump about 24% premarket

    Treace Medical reported Q2 revenue of $45.4 million and an adjusted loss of $0.24 per share, with both revenue and EPS beating consensus estimates. The company cut operating expenses by 8% and reduced cash burn since the start of the year by 57%, lowering the net loss to $15.9 million. Treace slightly raised its full-year revenue guidance to $204–212 million and narrowed the adjusted EBITDA loss to $3–5 million, citing accelerated case volume and several product launches as drivers. The stock rose about 24% in premarket trading in response to the stronger results and the improved outlook. » Mere på de.investing.com


  • Treace Medical Concepts reports Q4 2025 revenue decline, stock rises slightly

    Treace Medical Concepts reported Q4 2025 revenue of $62.5 million, a 9% decline year‑over‑year, and a loss per share of $0.16, missing expectations. Gross margin remained stable at 80.6%, while operating expenses rose slightly to $56.3 million. The company attributed the revenue decline to a shift in the product mix toward lower‑priced offerings. The stock gained 0.48% in premarket trading, and Treace plans several product launches in 2026 (including Lapiplasty Lightning and IntelliGuide PSI) to support growth. » Mere på de.investing.com


  • Treace Medical adjusts strategy: product expansion and cost cuts to counter falling demand

    Treace Medical reports annual revenue of over $200 million but sees weaker demand for the Lapoplasty system. The company is expanding its portfolio for bunion treatments, introducing new lower-priced products, and stepping up surgeon training as well as AI-powered diagnostics with IntelliGuide. Financial measures include stable gross margins in the high-70% range and a 45% reduction in cash burn; further decisions are expected after the Q4 numbers. » Mere på de.investing.com


  • Treace Medical raises Q3 revenue 11% to $50.2m but remains loss-making

    Treace Medical reported Q3 2025 revenue up 11% to $50.2m, above analysts’ estimate of $49.66m. The company recorded a net loss of $16.3m, or $0.26 per share; gross margin fell to 79.1%. Adjusted EBITDA loss improved 49% to $2.6m. For 2025 Treace expects revenue of $211–213m and an adjusted EBITDA loss of $6.5–7.5m; management emphasizes a focus on profitability and market expansion. » Mere på de.investing.com


  • Treace Medical Concepts beats Q2 forecasts and shares rise after hours

    Treace Medical Concepts Inc. reported a Q2 2025 loss per share of $0.28 versus $0.29 expected and revenue of $47.4 million, topping estimates. Net loss and adjusted EBITDA improved significantly; the stock rose 3.84% after hours. For 2025, the company guides to $224–$230 million in revenue and breakeven on adjusted EBITDA, supported by new product launches and market expansion. » Mere på de.investing.com

Virksomhedstal

I det seneste kvartal havde Treace Medical Concepts en omsætning på 42,6 mio. € og et nettoresultat på -11,09 mio. €
(EUR) september 2026
YoY
Omsætning 42,6 mio. 0,44 %
Bruttofortjeneste 33,86 mio. 0,07 %
Nettoresultat -11,09 mio. 20,07 %
EBITDA -9,7 mio. 6,52 %

Fundamentale data

Nøgletal Værdi
Markedsværdi
264,93 mio. €
Antal aktier
65,56 mio.
Højeste/laveste i 52 uger
4,95 € - 1,06 €
Udbytte Nej
Beta
1,56
P/E (PE Ratio)
-5,16
PEG (PEG Ratio)
0,49
K/I (PB Ratio)
4,72
P/S (PS Ratio)
1,43

Virksomhedsprofil

Treace Medical Concepts, Inc. er en ortopædisk medicinsk udstyrsvirksomhed, der designer, fremstiller og markedsfører medicinsk udstyr til fod- og ankelkirurger i USA. Virksomheden tilbyder Lapiplasty-proceduren, som gør det muligt for podiatriske kirurger at behandle alle tre dimensioner af hallux valgus (vabler), hvilket giver patienterne en kosmetisk og medicinsk forbedring. Virksomheden leverer også Lapiplasty Mini-Incision precisionssystemet. Derudover tilbyder den produkter til at håndtere supplerende kirurgiske procedurer, herunder akin-osteotomier, weil-osteotomier, intercuneiform-stabilisering, fusioner af den laterale tarsometatarsale led samt høst af autograft-knogle, og også til MTP-fusion. Treace Medical Concepts, Inc. blev grundlagt i 2013 og har hovedkontor i Ponte Vedra Beach, Florida.

Navn
Treace Medical Concepts
CEO
John T. Treace
Hjemsted Ponte Vedra, fl
USA
Websted
Sektor
Cykliske forbrugsvarer
Branche
Forbrugsgoder
Børsnotering
23.04.2021
Medarbejdere 450

Tickersymboler

Børs Symbol
NASDAQ
TMCI
🍪

Parqet  bruger cookies. Læs mere